Glenmark Pharmaceuticals on Monday (February 24, 2025) mentioned it’s going to pay USD 7 million to three entities to settle lawsuits in the U.S. associated to generic medication.
In a regulatory submitting, the Mumbai-based drug maker mentioned that in 2023 it had settled with three plaintiff teams referred because the Direct Purchaser Plaintiffs, the Retailer Plaintiffs, and the End-Payor Plaintiffs.
Four End-Payor Plaintiffs, Humana Inc, Centene, Kaiser Foundation Health Plan, Inc, and United Healthcare Services, Inc opted out of the 2023 settlements, it mentioned.
The 4 lawsuits, which included claims associated to each generic Zetia and Vytorin, had been subsequently remanded to the jurisdictions in which they had been initially filed.
“With a view to resolve this dispute and avoid uncertainty, Glenmark has agreed to enter into a settlement with three plaintiffs, Humana, Centene and Kaiser, for a total of USD 7 million,” the drug agency mentioned.
The settlement makes clear that Glenmark denies each one of many allegations towards it and the settlement shouldn’t be on the premise of the drugmaker having conceded or admitted any legal responsibility or illegality, it added.
Glenmark mentioned it alongside with subsidiary GlenmarkPharmaceuticals Inc, USA confronted a number of antitrust and client safety lawsuits, together with a category motion, consolidated in the Eastern District of Virginia, U.S. in connection with generic Zetia, a drug for the therapy of ldl cholesterol.
Four of these lawsuits additionally included claims associated to Vytorin, a Zetia mixture drug for the therapy of ldl cholesterol.
The lawsuits alleged that in 2010, Glenmark entered an anticompetitive settlement to settle patent infringement litigation involving a patent associated to ezetimibe (the lively ingredient in Zetia) with Schering Corporation and MSP Singapore Company LLC.
In the antitrust and client safety litigation, the corporate was named as a defendant alongside with Schering Corporation, MSP Singapore Company LLC, Merck & Co, Inc, Merck Sharp & Dohme Corp (now referred to as Merck Sharp & Dohme LLC), and Schering-Plough Corp.
Glenmark and Merck disputed these claims and defended these issues vigorously.
Glenmark shares had been buying and selling 2.21% up at ₹1,328.95 apiece on BSE.
Published – February 24, 2025 04:42 pm IST
